The role of anticitrullinated protein antibodies in the early stages of rheumatoid arthritis

Current Opinion in Rheumatology

Volumn 28, Issue 3, 2016, Pages 275-281

  Dekkers, Jarthritis Jacqueline ^a   Toes, Rene E M ^a   Huizinga, Tom W J ^a   Van Der Woude, Diane ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antibodies to citrullinated protein antigens; Anticitrullinated protein antibodies producing B cells; Autoantibodies; Rheumatoid arthritis

Indexed keywords

ANTICITRULLINATED PROTEIN ANTIBODY; AUTOANTIGEN; HLA A2 ANTIGEN; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; BIOLOGICAL MARKER;

ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; AUTOIMMUNITY; DISEASE ASSOCIATION; GLYCOSYLATION; HUMAN; LEUKOCYTE; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; IMMUNOLOGY; METABOLISM; PROGNOSIS;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNITY; BIOMARKERS; HUMANS; PROGNOSIS;

EID: 84960157998     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000277     Document Type: Review

References (65)

1. Vincent C, Serre G, Fournie B, et al. Natural IgG to epidermal cytokeratins vs IgG to the stratum corneum of the rat oesophagus epithelium, so-called 'antikeratin antibodies', in rheumatoid arthritis and other rheumatic diseases. J Autoimmun 1991; 4:493-505
2. Schellekens GA, Jong BA, van den Hoogen FH, et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998; 101:273-281
3. Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 2003; 25:1106-1118
4. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69:1580-1588
5. Rantapaa-Dahlqvist S, Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48:2741-2749
6. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004; 50:380-386
7. Berglin E, Johansson T, Sundin U, et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 2006; 65:453-458
8. Shi J, van Stadt LA, LevarhtEW, et al. Anticarbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis 2014; 73:780-783
9. Terao C, Ohmura K, Ikari K, et al. Effects of smoking and shared epitope on the production of anticitrullinated peptide antibody in a Japanese adult population. Arthritis Care Res (Hoboken) 2014; 66:1818-1827
10. van der Woude D, Rantapaa-Dahlqvist S, Ioan-Facsinay A, et al. Epitope spreading of the anticitrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis 2010; 69:1554-1561
11. Ioan-Facsinay A, Willemze A, Robinson DB, et al. Marked differences in fine specificity and isotype usage of the anticitrullinated protein antibody in health and disease. Arthritis Rheum 2008; 58:3000-3008
12. van Stadt LA, Koning MH, van Stadt RJ, et al. Development of the anticitrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. Arthritis Rheum 2011; 63:3226-3233
13. van Stadt LA, van der Horst AR, Koning MH, et al. The extent of the anticitrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia. Ann Rheum Dis 2011; 70:128-133
14. Brink M, Hansson M, Mathsson L, et al. Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis Rheum 2013; 65:899-910
15. Rombouts Y, Ewing E, van Stadt LA, et al. Anticitrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. Ann Rheum Dis 2015; 74:234-241
16. Koning F, Thomas R, Rossjohn J, Toes RE. Coeliac disease and rheumatoid arthritis: similar mechanisms, different antigens. Nat Rev Rheumatol 2015; 11:450-461
17. Kastbom A, Forslind K, Ernestam S, et al. Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial. Ann Rheum Dis 2014; pii: annrheumdis-2014-205698. [Epub ahead of print]
18. van Beers JJ, Willemze A, Jansen JJ, et al. ACPA fine-specificity profiles in early rheumatoid arthritis patients do not correlate with clinical features at baseline or with disease progression. Arthritis Res Ther 2013; 15:R140
19. Scherer HU, van der Woude D, Willemze A, et al. Distinct ACPA fine specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis. Ann Rheum Dis 2011; 70:1461-1464
20. Fisher BA, Plant D, Brode M, et al. Antibodies to citrullinated alpha-enolase peptide 1 and clinical and radiological outcomes in rheumatoid arthritis. Ann Rheum Dis 2011; 70:1095-1098
21. Amara K, Steen J, Murray F, et al. Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition. J Exp Med 2013; 210:445-455
22. Suwannalai P, Scherer HU, van der Woude D, et al. Anticitrullinated protein antibodies have a low avidity compared with antibodies against recall antigens. Ann Rheum Dis 2011; 70:373-379
23. Suwannalai P, van Stadt LA, Radner H, et al. Avidity maturation of anticitrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 2012; 64:1323-1328
24. Trouw LA, Haisma EM, Levarht EWN, et al. Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis Rheum 2009; 60:1923-1931
25. Anquetil F, Clavel C, Offer G, et al. IgM and IgA rheumatoid factors purified from rheumatoid arthritis sera boost the Fc receptor-and complementdependent effector functions of the disease-specific anticitrullinated protein autoantibodies. J Immunol 2015; 194:3664-3674
26. Suurmond J, Rivellese F, Dorjee AL, et al. Toll-like receptor triggering augments activation of human mast cells by anticitrullinated protein antibodies. Ann Rheum Dis 2015; 74:1915-1923
27. Kokkonen H, Mullazehi M, Berglin E, et al. Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthritis Res Ther 2011; 13:R13
28. van der Woude D, Syversen SW, van der Voort EI, et al. The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis. Ann Rheum Dis 2010; 69:1110-1116
29. Scherer HU, van der Woude D, Ioan-Facsinay A, et al. Glycan profiling of anticitrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum 2010; 62:1620-1629
30. Lundstrom SL, Fernandes-Cerqueira C, Ytterberg AJ, et al. IgG antibodies to cyclic citrullinated peptides exhibit profiles specific in terms of IgG subclasses, Fc-glycans and a Fab-peptide sequence. PLoS One 2014; 9:e113924
31. Karsten CM, Kohl J. The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases. Immunobiology 2012; 217:1067-1079
32. Huizinga TW, Amos CI, Helm-van Mil AH, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 2005; 52:3433-3438
33. Oka S, Furukawa H, Kawasaki A, et al. Protective effect of the HLADRB1 13 02 allele in Japanese rheumatoid arthritis patients. PLoS One 2014; 9:e99453
34. van der Woude D, Lie BA, Lundstrom E, et al. Protection against anticitrullinated protein antibody-positive rheumatoid arthritis is predominantly associated with HLA-DRB11301: a meta-analysis of HLA-DRB1 associations with anticitrullinated protein antibody-positive and anticitrullinated protein antibody-negative rheumatoid arthritis in four European populations. Arthritis Rheum 2010; 62:1236-1245
35. Han B, Diogo D, Eyre S, et al. Fine mapping seronegative and seropositive rheumatoid arthritis to shared and distinct HLA alleles by adjusting for the effects of heterogeneity. Am J Hum Genet 2014; 94:522-532
36. Stastny P. Mixed lymphocyte cultures in rheumatoid arthritis. J Clin Invest 1976; 57:1148-1157
37. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30:1205-1213
38. Raychaudhuri S, Sandor C, Stahl EA, et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet 2012; 44:291-296
39. Scally SW, Petersen J, Law SC, et al. A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J Exp Med 2013; 210:2569-2582
40. Feitsma AL, van der Voort EIH, Franken KLMC, Ioan-Facsinay A. Identification of citrullinated vimentin peptides as T cell epitopes in HLADR4-positive patients with rheumatoid arthritis. Arthritis Rheum 2010; 62:117-125
41. James EA, Rieck M, Pieper J, et al. Citrulline-specific Th1 cells are increased in rheumatoid arthritis and their frequency is influenced by disease duration and therapy. Arthritis Rheum 2014; 66:1712-1722
42. Law SC, Street S, Yu CHA, et al. T-cell autoreactivity to citrullinated autoantigenic peptides in rheumatoid arthritis patients carrying HLA-DRB1 shared epitope alleles. Arthritis Res Ther 2012; 14:R118
43. van Beers JJ, Schwarte CM, Stammen-Vogelzangs J, et al. The rheumatoid arthritis synovial fluid citrullinome reveals novel citrullinated epitopes in apolipoprotein E, myeloid nuclear differentiation antigen, and beta-actin. Arthritis Rheum 2013; 65:69-80
44. van Heemst J, Jansen DTSL, Polydorides S, et al. Crossreactivity to vinculin and microbes provides a molecular basis for HLA-based protection against rheumatoid arthritis. Nat Commun 2015; 6:6681
45. Courvoisier N, Dougados M, Cantagrel A, et al. Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study. Arthritis Res Ther 2008; 10:R106
46. Syversen SW, Goll GL, van der Heijde D, et al. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study. Ann Rheum Dis 2010; 69:345-351
47. Plant D, Thomson W, Lunt M, et al. The role of rheumatoid arthritis genetic susceptibility markers in the prediction of erosive disease in patients with early inflammatory polyarthritis: results from the Norfolk Arthritis Register. Rheumatology (Oxford) 2011; 50:78-84
48. Jilani AA, Mackworth-Young CG. The role of citrullinated protein antibodies in predicting erosive disease in rheumatoid arthritis: a systematic literature review and meta-analysis. Int J Rheumatol 2015; 2015:728610
49. Kleyer A, Finzel S, Rech J, et al. Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis 2014; 73:854-860
50. Cambridge G, Leandro MJ, Edwards JC, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003; 48:2146-2154
51. Nakou M, Katsikas G, Sidiropoulos P, et al. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther 2009; 11:R131
52. Trouvin AP, Jacquot S, Grigioni S, et al. Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study. Clin Exp Immunol 2015; 180:11-18
53. Snir O, Widhe M, Hermansson M, et al. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum 2010; 62:44-52
54. Kerkman PF, Rombouts Y, van der Voort EIH, et al. Circulating plasmablasts/ plasmacells as a source of anticitrullinated protein antibodies in patients with rheumatoid arthritis. Ann Rheum Dis 2013; 72:1259-1263
55. Laurent L, Clavel C, Lemaire O, et al. Fc gamma receptor profile of monocytes and macrophages from rheumatoid arthritis patients and their response to immune complexes formed with autoantibodies to citrullinated proteins. Ann Rheum Dis 2011; 70:1052-1059
56. Carmona-Rivera C, Khandpur R, Vivekanandan-Giri A, et al. Neutrophil extracellular traps are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med 2013; 5:178ra40
57. Harre U, Georgess D, Bang H, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 2012; 122:1791-1802
58. Kuhn KA, Kulik L, Tomooka B, et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 2006; 116:961-973
59. Uysal H, Bockermann R, Nandakumar KS, et al. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J Exp Med 2009; 206:449-462
60. Begley CG, Ellis LM. Drug development: raise standards for preclinical cancer research. Nature 2012; 483:531-533
61. Scarsi M, Paolini L, Ricotta D, et al. Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. J Rheumatol 2014; 41:666-672
62. Barra L, Bykerk V, Pope JE, et al. Anticitrullinated protein antibodies and rheumatoid factor fluctuate in early inflammatory arthritis and do not predict clinical outcomes. J Rheumatol 2013; 40:1259-1267
63. Humphreys J, Verheul M, Barton A, et al. Association of anticarbamylated protein antibodies with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. Lancet 2015; 385 (Suppl 1):S44
64. Brink M, Verheul MK, Ronnelid J, et al. Anticarbamylated protein antibodies in the presymptomatic phase of rheumatoid arthritis, their relationship with multiple anticitrulline peptide antibodies and association with radiological damage. Arthritis Res Ther 2015; 17:25
65. Thiele GM, Duryee MJ, Anderson DR, et al. Malondialdehyde-acetaldehyde adducts and antimalondialdehyde-acetaldehyde antibodies in rheumatoid arthritis. Arthritis Rheumatol 2015; 67:645-655